Clopidogrel NDC 68071-4138

NDC codes

FDA NDC Directory

Product NDC (as listed)68071-4138Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68071-4138Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68071-4138-3	68071413803	30 TABLET, FILM COATED in 1 BOTTLE (68071-4138-3)Marketed from Oct 31, 2017

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Clopidogrel
Generic name (nonproprietary): clopidogrel
Active ingredients: Clopidogrel bisulfate — 75 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: NuCare Pharmaceuticals,Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076999
Marketing start: May 17, 2012
Listing expires: Dec 31, 2026
Other FDA classes: Cytochrome P450 2C8 Inhibitors (Mechanism)Decreased Platelet Aggregation (Physiologic effect)P2Y12 Receptor Antagonists (Mechanism)
Identifiers: Product ID 68071-4138_2d3fdef2-fc4a-c8e1-e063-6394a90a0aa5SPL ID 2d3fdef2-fc4a-c8e1-e063-6394a90a0aa5SPL set ID 5cdca9bd-7042-142a-e053-2991aa0a9ca6RxCUI 309362UNII 08I79HTP27
Pharmacologic class: P2Y12 Platelet Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468071413803 followed by a unit qualifier and the quantity

Package 68071-4138-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 3, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Clopidogrel tablets are a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel tablets have been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets have been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets have been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Clopidogrel tablets are indicated to reduce the rate of m…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 076999

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 076999
Product	Strength	Form · route	Labeler	Product NDC
Clopidogrel	Clopidogrel bisulfate 75 mg/1	Tablet, Film coatedOral	Proficient Rx LP	63187-362
Clopidogrel	Clopidogrel bisulfate 75 mg/1	Tablet, Film coatedOral	Teva Pharmaceuticals USA, Inc.	0093-7314